The GBM pattern additionally classifies the patients with either a methylated or an unmethylated MGMT promoter, or a mutated or an unmutated IDH1, into two groups each, with an approximately one-year to >4-year survival differences, which means that it is independent of both. Here, IDH1 is linked to glioblastoma.